[go: up one dir, main page]

WO2007069271A3 - Process for the purification of (s) -n- (l-carboxy-2-methyl-prop-1-yl) -n-pentanoyl-n- [2' - (1h-tetraz0l-5-yl) bipheny l-4 -ylmethyl] -amine (valsartan) - Google Patents

Process for the purification of (s) -n- (l-carboxy-2-methyl-prop-1-yl) -n-pentanoyl-n- [2' - (1h-tetraz0l-5-yl) bipheny l-4 -ylmethyl] -amine (valsartan) Download PDF

Info

Publication number
WO2007069271A3
WO2007069271A3 PCT/IN2006/000426 IN2006000426W WO2007069271A3 WO 2007069271 A3 WO2007069271 A3 WO 2007069271A3 IN 2006000426 W IN2006000426 W IN 2006000426W WO 2007069271 A3 WO2007069271 A3 WO 2007069271A3
Authority
WO
WIPO (PCT)
Prior art keywords
pentanoyl
ylmethyl
prop
carboxy
amine
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/IN2006/000426
Other languages
French (fr)
Other versions
WO2007069271A2 (en
Inventor
Pandurang Balwant Deshpande
Parven Kumar Luthra
Anand Kumar Pandey
Kamlesh Sanmukhbhai Soni
Ravindra Charudatta Ghotikar
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Alembic Ltd
Original Assignee
Alembic Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Alembic Ltd filed Critical Alembic Ltd
Publication of WO2007069271A2 publication Critical patent/WO2007069271A2/en
Anticipated expiration legal-status Critical
Publication of WO2007069271A3 publication Critical patent/WO2007069271A3/en
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D257/00—Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms
    • C07D257/02—Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D257/04—Five-membered rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

The present invention relates to process for purification of (S)-N-(1-Carboxy-2-methyl-prop-1-yl)-N-pentanoyl-N-[2'-(1H-tetrazol-5-yl)biphenyl-4-ylmethyl]-amine.
PCT/IN2006/000426 2005-10-31 2006-10-19 Process for the purification of (s) -n- (l-carboxy-2-methyl-prop-1-yl) -n-pentanoyl-n- [2' - (1h-tetraz0l-5-yl) bipheny l-4 -ylmethyl] -amine (valsartan) Ceased WO2007069271A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IN1375MU2005 2005-10-31
IN1375/MUM/2005 2005-10-31

Publications (2)

Publication Number Publication Date
WO2007069271A2 WO2007069271A2 (en) 2007-06-21
WO2007069271A3 true WO2007069271A3 (en) 2008-10-02

Family

ID=38163339

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IN2006/000426 Ceased WO2007069271A2 (en) 2005-10-31 2006-10-19 Process for the purification of (s) -n- (l-carboxy-2-methyl-prop-1-yl) -n-pentanoyl-n- [2' - (1h-tetraz0l-5-yl) bipheny l-4 -ylmethyl] -amine (valsartan)

Country Status (1)

Country Link
WO (1) WO2007069271A2 (en)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2057132A2 (en) 2006-07-03 2009-05-13 Aurobindo Pharma Limited Process for the preparation of the angiotensin ii antagonist valsartan
AR082435A1 (en) * 2010-08-03 2012-12-05 Novartis Ag HIGHLY CRYSTAL VALSARTAN
CN102617497B (en) * 2012-02-27 2015-02-11 浙江新赛科药业有限公司 Process for refining valsartan
CN103819421A (en) 2014-02-21 2014-05-28 浙江华海药业股份有限公司 Refining method of valsartan containing more than 10% of isomer

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004094391A2 (en) * 2003-04-21 2004-11-04 Teva Pharmaceutical Industries Ltd. Process for the preparation of valsartan and intermediates thereof
WO2005049587A1 (en) * 2003-11-21 2005-06-02 Ranbaxy Laboratories Limited Process for preparation of biphenyl tetrazole

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004094391A2 (en) * 2003-04-21 2004-11-04 Teva Pharmaceutical Industries Ltd. Process for the preparation of valsartan and intermediates thereof
WO2005049587A1 (en) * 2003-11-21 2005-06-02 Ranbaxy Laboratories Limited Process for preparation of biphenyl tetrazole

Also Published As

Publication number Publication date
WO2007069271A2 (en) 2007-06-21

Similar Documents

Publication Publication Date Title
WO2003093269A3 (en) Substituted pyrazolo-pyrimidine-4-ones
WO2007127263A3 (en) Therapeutic uses of urolithins
WO2008029096A8 (en) P53 activating benzoyl urea and benzoyl thiourea compounds
IL190137A0 (en) Crystals of laquinimod sodium, and process for the manufacture thereof
WO2009016462A3 (en) Substituted bicyclolactam compounds
WO2008046581A3 (en) Substituted tetrahydropyrrolopyrazine compounds and use thereof in medicaments
WO2008136394A1 (en) Method for production of lactam compound, and intermediate for the production method
WO2008045371A3 (en) N-substituted-azacyclylamines as histamine-3 antagonists
WO2006039250A3 (en) Chemokine-binding heterocyclic compound salts, and methods of use thereof
WO2008019030A8 (en) Modified azole compounds as antiinfective agents
WO2006029193A3 (en) Process for preparing substituted tetrazoles from aminotetrazole
WO2009035959A3 (en) Radiofluorination methods
WO2007104485A3 (en) Substituted imidazo[2,1-b]thiazole compounds and their use for producing drugs
WO2009009122A3 (en) Derivatives of urea and related diamines, methods for their manufacture, and uses therefor
WO2007014762A3 (en) Glyt1 transporter inhibitors and uses thereof in treatment of neurological and neuropsychiatric disorders
WO2007022947A3 (en) 5-ring heteroaromatic compounds and their use as binding partners for 5-ht5 receptors
WO2007032019A3 (en) Process for preparing valsartan
WO2007069271A3 (en) Process for the purification of (s) -n- (l-carboxy-2-methyl-prop-1-yl) -n-pentanoyl-n- [2' - (1h-tetraz0l-5-yl) bipheny l-4 -ylmethyl] -amine (valsartan)
WO2006107062A3 (en) Benzimidazole derivative and use as angiotensin ii antagonist
WO2008035360A3 (en) Novel crystalline forms of candesartan cilexetil, candesartan, tritylated candesartan and tritylated candesartan cilexetil
WO2006134499A3 (en) 2-(1h-indolylsulfanyl)-aryl amine derivatives
EP1896433A4 (en) Novel crystalline forms of (s)-n-(1-carboxy-2-methyl-prop-1-yl)-n-pentanoyl-n-[2'-(1h-tetrazol-5-yl)bi-phenyl-4-ylmethyl]-amine
WO2007009589A3 (en) Use of soluble guanylate cyclase for the treatment of raynaud's phenomenon
WO2008083191A3 (en) Radiofluorination methods
WO2007002722A3 (en) Synthesis of anastrozole and purification of one of its intermediate

Legal Events

Date Code Title Description
NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 06848602

Country of ref document: EP

Kind code of ref document: A2